Sapient Contributes to Novel Findings Published in European Heart Journal Identifying Metabolite and Protein Signatures of Cardiotoxicity in Breast Cancer Patients

August 25, 2026 – San Diego, CA – Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has contributed to new research published in European Heart Journal which provides novel insight into the underlying biological perturbations that occur in breast cancer patients receiving cardiotoxic therapies – identifying new metabolite and protein signatures associated with cardiac dysfunction and remodelling in these patients.

Led by a prominent industry-academia research collaborative, the multi-omics study paired large-scale proteomics profiling with Sapient’s rapid liquid chromatography-mass spectrometry (rLC-MS) discovery metabolomics platform to comprehensively characterize longitudinal associations between circulating molecules and cardiac function. This analysis revealed 16 unique metabolites significantly associated with measures of cardiac structure and function, including five key metabolite biomarkers specifically linked to left ventricular ejection fraction (LVEF) and longitudinal strain. Importantly, it uniquely uncovered an association between aspartic acid and cancer therapy-related cardiac remodelling. From the proteomics analysis, cathepsin C (CTSC) stood out as a key protein biomarker with the strongest association with longitudinal strain.

As one of the largest longitudinal studies in cardio-oncology to date, encompassing 547 breast cancer patients, these findings provide new robust data on biomarkers and pathways involved in cancer therapy-related cardiotoxicity with the potential to identify patients at risk for such complications. “Cardiotoxicity from cancer therapy is a real and growing concern for patients and oncologists, and more sensitive, specific biomarkers are urgently needed to improve cardiotoxicity risk prediction,” said Dr. Tao Long, Co-Founder and Head of Data Science at Sapient and a contributing author to the study. “We were able to contribute deep metabolomic profiling, looking across tens of thousands of metabolites and lipids per sample from breast cancer patients on cardiotoxic therapies, to identify novel associations between metabolites and cardiac remodelling and dysfunction over time – those that would not have been found through more traditional targeted metabolomics approaches.”

“Today oncologists largely rely on periodic echocardiograms to monitor for cardiotoxicity, but they catch damage after it has already occurred,” added Dr. Mo Jain, Founder and Chief Scientific Officer at Sapient, also a contributing author to the study. “These research findings show the real potential of discovery metabolomics and proteomics applied at scale to identify novel circulating biomarkers – both metabolites and proteins which change dynamically in response to therapeutic pressure – to support earlier diagnosis and even prediction of cancer therapy-related cardiac dysfunction and remodelling.”

The full paper, entitled “Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling”, can be accessed here.

###

About Sapient

Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development.

Utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks, Sapient enables comprehensive biomarker-phenotype mapping across thousands of biosamples for discovery of robust protein, metabolite, and lipid biomarkers, drug targets, and clinical signatures of drug response. The company’s DynamiQ™ Insights Engine – a longitudinal molecular-clinical database collected from tens of thousands of human samples – enables rapid drug target identification, biomarker discovery and validation, and translational and clinical insights across all stages of drug development. For more information, visit sapient.bio.

Media Contact:
Carla Nieser
Head of Marketing, Sapient
carla.nieser@sapient.bio
858.290.7010